Prognostic Factors in Patients with Refractory and Relapsed Acute Lymphocytic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (IO), a CD22 Monoclonal Antibody
Title:
Prognostic Factors in Patients with Refractory and Relapsed Acute Lymphocytic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (IO), a CD22 Monoclonal Antibody
Author:
Sasaki, Koji Jabbour, Elias O’Brien, Susan Huang, Xuelin Thomas, Deborah Rytting, Michael Garcia-Manero, Guillermo Cortes, Jorge Pierce, Sherry Kadia, Tapan Kantarjian, Hagop